Squarepoint’s Praxis Precision Medicines PRAX Stock Holding History

Squarepoint’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Sell	5,700 -3,300	-37%	-$1.04M	﹤0.01%	2377
2026 Q1	$2.9M	Buy	+9,000	New	+$2.78M	﹤0.01%	1913

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Squarepoint's PRAX Position: Q2 2026 in Review

Squarepoint increased its Praxis Precision Medicines (PRAX) stake by 2,014% in Q2 2026, buying an estimated $12.8M and bringing the position to 42,501 shares worth $14.2M. The position accounts for 0.02% of the portfolio, ranked #873.

Squarepoint first reported a position in PRAX in Q2 2021 and has held it in 12 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Squarepoint held 42,501 shares of Praxis Precision Medicines worth $14.2M as of Q2 2026.
Squarepoint bought 40,491 Praxis Precision Medicines shares in Q2 2026, an estimated $12.8M.
Praxis Precision Medicines made up 0.02% of Squarepoint's portfolio in Q2 2026, its #873 holding.
Squarepoint first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 12 quarters since.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.